Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Oxygen chamber hope: could HBOT treat long COVID, Crohn's, and more?

NCT ID NCT07240649

First seen Nov 21, 2025 · Last updated Jun 23, 2026 · Updated 26 times

Summary

This study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, ulcerative colitis, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of life. The goal is to gather data to support wider use of this treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber

What this could lead to

If it works, this could expand the use of HBOT to treat many conditions that currently have limited options, potentially improving quality of life for thousands of patients.

What could go wrong

This is an early registry study, not a controlled trial, so results may be less reliable. HBOT also has risks like ear pain, sinus damage, and, rarely, lung collapse.

Conditions

The condition(s) this trial relates to.

acute intestinal ischemia anterior ischemic optic neuropathy avascular necrosis branch retinal artery occlusion calciphylaxis central retinal vein occlusion chronic cystitis Clostridium difficile colitis Craniocerebral Trauma Crohn disease decubitus ulcer epidermolysis bullosa frostbite graft versus host disease head injury hypospadias inclusion body myositis Invasive Fungal Infections ligament disorder malignant otitis externa multiple sclerosis nervous system injury non-arteritic anterior ischemic optic neuropathy osteonecrosis pneumatosis cystoides intestinalis post-COVID-19 disorder pouchitis prosthesis-related infectious disease pterygium pyoderma gangrenosum Raynaud disease Rectovaginal Fistula retinal artery occlusion retinal vein occlusion systemic mycosis tinnitus ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.